摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,2,3,4,4a,5,6,7-Octahydroquinoline | 876509-33-0

中文名称
——
中文别名
——
英文名称
1,2,3,4,4a,5,6,7-Octahydroquinoline
英文别名
——
1,2,3,4,4a,5,6,7-Octahydroquinoline化学式
CAS
876509-33-0
化学式
C9H15N
mdl
——
分子量
137.22
InChiKey
CEKSPMMCISUSTR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.78
  • 拓扑面积:
    12
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为产物:
    描述:
    1-benzyl-6-hydroxy-1,2,3,4,5,6,7,8-octahydroquinoline 、 1-benzyl-6-hydroxy-1,2,3,4,4a,5,6,7-octahydroquinoline 、 Lithium aluminium hydride 在 ice water 、 氮气乙酸乙酯sodium hydroxide氯仿氯化钠 、 2-oxo 、 6-benzoyloxy 作用下, 以 四氢呋喃 为溶剂, 反应 4.0h, 以to yield an octahydroquinoline with a free alcohol at C-6)的产率得到1,2,3,4,4a,5,6,7-Octahydroquinoline
    参考文献:
    名称:
    Method of using octahydro pyrazolo[3,4-g]quinolines
    摘要:
    通过给予一种5-(C.sub.1-C.sub.3)烷基或烯丙基-7-可置换-4,4a,5,6,7,8,8a,9-八氢-1H-吡唑并[3,4-g]喹啉的互变异构体混合物来治疗帕金森综合症的方法。
    公开号:
    US04367231A1
点击查看最新优质反应信息

文献信息

  • Azabicyclic compounds are central nervous system active agents
    申请人:——
    公开号:US20040044029A1
    公开(公告)日:2004-03-04
    Compounds of formula (I) 1 are novel CNS active agents that are useful for treating pain and for treating other disorders associated with the cholinergic system.
    公式(I)1的化合物是新颖的中枢神经系统活性剂,用于治疗疼痛以及治疗与胆碱能系统相关的其他疾病。
  • Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
    申请人:SANKYO COMPANY, LIMITED
    公开号:US20040054173A1
    公开(公告)日:2004-03-18
    Compounds having activity against production of an inflammatory cytokine of formula (I)′: 1 A′ is pyrrole; R 1′ is phenyl or naphthyl; R 2′ is pyridyl or pyrimidinyl; R 3′ is (IIa)′, (IIb)′ or (IIc)′: 2 m′ is 1; E′ is nitrogen; D′ is >C(R 5′ )—, R 5′ is hydrogen, Substituent &agr;′ or Substituent &bgr;′; B′ is nitrogen-containing 5-membered heterocyclic; R 4′ is 1 to 3 substituents from Substituent &agr;′, Substituent &bgr;′ and Substituent &ggr;′; R 1′ and R 3′ are bonded to two atoms of the pyrrole adjacent to the pyrrole atom bonded to R 2′ ; Substituent &agr;′ is hydroxyl, nitro, cyano, halogen, alkoxy, halogeno alkoxy, alkylthio, halogeno alkylthio or —NR a′ R b′ ; R a′ and R b′ are hydrogen, alkyl, alkenyl, alkynyl, aralkyl or alkylsulfonyl, or R a′ and R b′ with the nitrogen atom form a heterocyclyl; Substituent &bgr;′ is alkyl, alkenyl, alkynyl, aralkyl or cycloalkyl; Substituent &ggr;′ is oxo, hydroxyimino, alkoxyimino, alkylene, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, aryl, aryloxy, alkylidenyl or aralkylidenyl.
    具有对抗公式(I)′炎症细胞因子生成活性的化合物: 1 A′是吡咯;R 1′ 是苯基或萘基;R 2′ 是吡啶基或嘧啶基;R 3′ 是(IIa)′,(IIb)′或(IIc)′: 2 m′是1;E′是氮;D′是>C(R 5′ )—, R 5′ 是氢,取代基α′或取代基β′;B′是含氮的5-成员杂环;R 4′ 是来自取代基α′,取代基β′和取代基γ′的1至3个取代基;R 1′ 和R 3′ 分别与吡咯环上与R 2′ 相连的吡咯原子的两个相邻原子成键;取代基α′是羟基,硝基,氰基,卤素,烷氧基,卤代烷氧基,烷基亚砜,卤代烷基亚砜或—NR a′ R b′ ;R a′ 和R b′ 是氢,烷基,烯基,炔基,芳烷基或烷基亚磺酰基,或者R a′ 和R b′ 与氮原子形成杂环;取代基β′是烷基,烯基,炔基,芳烷基或环烷基;取代基γ′是氧代,羟基亚胺,烷氧基亚胺,亚烷基,亚烷基二氧,烷基亚磺酰基,烷基亚磺酰基,芳基,芳氧基,亚烷基或芳亚烷基。
  • Benzothiazole derivatives with activity as adenosine receptor ligands
    申请人:——
    公开号:US20020045615A1
    公开(公告)日:2002-04-18
    The present invention relates to substituted benzothiazole derivitives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.
    本发明涉及替代苯并噻唑衍生物及其药用可接受的盐,用于治疗与腺苷受体相关的疾病。
  • [EN] ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS<br/>[FR] ACIDES THIAZOLE CARBOXYLIQUES ANTIBACTÉRIENS
    申请人:ANTABIO SAS
    公开号:WO2014198849A1
    公开(公告)日:2014-12-18
    Compounds of general formula (I), wherein R1, R11, Y, R2, n and A are as defined herein are useful as inhibitors or metallo-β-lactamase (MBL) enzymes and can be used for reducing or removing antibiotic resistance in bacteria.
    通式(I)的化合物,其中R1、R11、Y、R2、n和A的定义如本文所述,可用作金属β-内酰胺酶(MBL)酶的抑制剂,并可用于减少或消除细菌中的抗生素抗性。
  • NITRILES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
    申请人:ONO PHARMACEUTICAL CO., LTD.
    公开号:EP1724264A1
    公开(公告)日:2006-11-22
    The present invention relates to a compound of formula (I) wherein Y and Z each is independently N or C; ring A is a carbocyclic group or a heterocyclic group; ring B is a heterocyclic group containing at least one nitrogen atom; R is a hydrogen atom, a substituent, etc,; n is 0, or an integer of from 1 to 10, a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof. The compound of formula (I), a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof has an inhibitory activity against cysteine protease, and it is useful for the prophylaxis and/or treatment of a cysteine protease-related disease such as osteoporosis, etc.
    本发明涉及一种具有以下式(I)的化合物,其中Y和Z各自独立地为N或C;环A为碳环基团或杂环基团;环B为含有至少一个氮原子的杂环基团;R为氢原子、取代基等;n为0,或为1至10的整数,其盐、溶剂合物、N-氧化物或前药。具有式(I)的化合物,其盐、溶剂合物、N-氧化物或前药对半胱氨酸蛋白酶具有抑制活性,对于预防和/或治疗半胱氨酸蛋白酶相关疾病如骨质疏松症等是有用的。
查看更多